Role of betulinic acid derivative SH‑479 in triple negative breast cancer and bone microenvironment

Tang,Liang; Lv,Shu Jun; Wu,Zhipeng; Qian,Ming; Xu,Yuduo; Gao,Xin; Wang,Tao; Guo,Wen; Hou,Tianhui; Li,Xiu; Li,Zhenxi; Zhao,Jian; Xiao,Jianru; Wei,Haifeng

doi:10.3892/ol.2021.12866

Role of betulinic acid derivative SH‑479 in triple negative breast cancer and bone microenvironment

Authors:
- Liang Tang
- Shu Jun Lv
- Zhipeng Wu
- Ming Qian
- Yuduo Xu
- Xin Gao
- Tao Wang
- Wen Guo
- Tianhui Hou
- Xiu Li
- Zhenxi Li
- Jian Zhao
- Jianru Xiao
- Haifeng Wei
View Affiliations

Affiliations: Spine Tumor Center, Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China, Department of Orthopedics, Hai'an People's Hospital, Jiangsu, Hai'an 226600, P.R. China, Department of Orthopedics, Taizhou People's Hospital, Jiangsu, Taizhou 225300, P.R. China
Published online on: June 15, 2021 https://doi.org/10.3892/ol.2021.12866
Article Number: 605
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer has a high prevalence in the general population and is often associated with bone metastasis. Specific therapeutic targets are missing for triple negative breast cancer (TNBC), which presents some immunogenic characteristics. Betulinic acid (BA) has been reported to have some anti‑tumor properties, and its modified derivative SH‑479 was demonstrated to inhibit TNBC bone metastasis. The present study aimed to investigate the effect of the BA derivative SH‑479 on breast cancer and bone microenvironment. The effect of BA and its derivative SH‑479 on MDA‑MB‑231 cell proliferation was determined with the MTS method. The cytotoxicity effect of SH‑479 was evaluated using the Live and Dead assay. Cell microfilament changes were observed by F‑actin staining. The effects of SH‑479 on PARP protein expression and cell cycle were detected by western blotting and flow cytometry, respectively. The migratory ability of breast cancer cells treated with SH‑479 was determined by migration assay. The effect of SH‑479 on osteoclast differentiation induced by breast cancer cells was observed using the osteoclast differentiation assay and tartrate‑resistant acid phosphatase staining. The effects of SH‑479 on T lymphocytes and bone marrow‑derived suppressor cells (MDSCs) in bone marrow from mice were observed by flow cytometry. The results demonstrated that SH‑479 significantly inhibited the proliferation of the TNBC cell line MDA‑MB‑231 at lower concentrations but had no significant effect on normal cells and other types of breast cancer cells for the same concentration. Furthermore, SH‑479 significantly interfered with actin microfilaments in breast cancer cells but had no effect on cell apoptosis and cell cycle. In addition, SH‑479 inhibited the migratory ability of breast cancer cells and the differentiation of osteoclasts induced by breast cancer cells. In bone marrow immune microenvironment, addition of SH‑479 could promote the proliferation of CD4+T lymphocytes and inhibit the proliferation of MDSCs. Taken together, the findings from this study demonstrated that SH‑479 inhibited the activity and migratory ability of TNBC cells and the differentiation of osteoclasts induced by TNBC and affected the bone marrow immune microenvironment. SH‑479 may therefore inhibit breast cancer metastasis to bones, indicating that SH‑479 may be considered as a promising drug to inhibit bone metastasis in patients with breast cancer.

View Figures

View References

1	Beiki O, Hall P, Ekbom A and Moradi T: Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: A population-based cohort study. Breast Cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
2	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
3	Buijs JT and van der Pluijm G: Osteotropic cancers: From primary tumor to bone. Cancer Lett. 273:177–193. 2009. View Article : Google Scholar : PubMed/NCBI
4	Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
5	Fang J and Xu Q: Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clin Transl Oncol. 17:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL and Clemons M: Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. J Bone Oncol. 2:137–144. 2013. View Article : Google Scholar : PubMed/NCBI
7	Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S and Purushotham A: Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 38:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
8	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI
9	Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
10	Oakman C, Viale G and Di Leo A: Management of triple negative breast cancer. Breast. 19:312–321. 2010. View Article : Google Scholar : PubMed/NCBI
11	Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, et al: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 110:876–884. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
13	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
14	Katz H and Alsharedi M: Immunotherapy in triple-negative breast cancer. Med Oncol. 35:132017. View Article : Google Scholar : PubMed/NCBI
15	Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10:194–200. 2009.PubMed/NCBI
16	Chowdhury AR, Mandal S, Mittra B, Sharma S, Mukhopadhyay S and Majumder HK: Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: Identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 8:BR254–BR265. 2002.PubMed/NCBI
17	Viji V, Helen A and Luxmi VR: Betulinic acid inhibits endotoxin-stimulated phosphorylation cascade and pro-inflammatory prostaglandin E(2) production in human peripheral blood mononuclear cells. Br J Pharmacol. 162:1291–1303. 2011. View Article : Google Scholar : PubMed/NCBI
18	de Melo CL, Queiroz MG, Arruda Filho AC, Rodrigues AM, de Sousa DF, Almeida JG, Pessoa OD, Silveira ER, Menezes DB, Melo TS, et al: Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. J Agric Food Chem. 57:8776–8781. 2009. View Article : Google Scholar : PubMed/NCBI
19	Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, Souchet M, Auwerx J, Saladin R and Wagner A: Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes. J Med Chem. 53:178–190. 2010. View Article : Google Scholar : PubMed/NCBI
20	de Sá MS, Costa JF, Krettli AU, Zalis MG, Maia GL, Sette IM, Câmara CA, Filho JM, Giulietti-Harley AM, Ribeiro Dos Santos R, et al: Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res. 105:275–279. 2009. View Article : Google Scholar
21	Aisha AF, Ismail Z, Abu-Salah KM, Siddiqui JM, Ghafar G and Abdul Majid AM: Syzygium campanulatum korth methanolic extract inhibits angiogenesis and tumor growth in nude mice. BMC Complement Altern Med. 13:1682013. View Article : Google Scholar : PubMed/NCBI
22	Fulda S: Betulinic acid: A natural product with anticancer activity. Mol Nutr Food Res. 53:140–146. 2009. View Article : Google Scholar : PubMed/NCBI
23	Xu J, Li Z, Luo J, Yang F, Liu T, Liu M, Qiu WW and Tang J: Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption. J Med Chem. 55:3122–3134. 2012. View Article : Google Scholar : PubMed/NCBI
24	Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature. 411:375–379. 2001. View Article : Google Scholar : PubMed/NCBI
25	Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
26	Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A and Ponnazhagan S: Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol. 189:4258–4265. 2012. View Article : Google Scholar : PubMed/NCBI
27	Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM and Karin M: Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 470:548–553. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sawant A and Ponnazhagan S: Myeloid-derived suppressor cells as osteoclast progenitors: A novel target for controlling osteolytic bone metastasis. Cancer Res. 73:4606–4610. 2013. View Article : Google Scholar : PubMed/NCBI
29	Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M and Aggarwal BB: Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood. 111:4880–4891. 2008. View Article : Google Scholar : PubMed/NCBI
30	Hou T, Lou Y, Li S, Zhao C, Ji Y, Wang D, Tang L, Zhou M, Xu W, Qian M, et al: Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway. Oncol Lett. 16:2255–2262. 2018.PubMed/NCBI
31	Li Z, Huang J, Wang F, Li W, Wu X, Zhao C, Zhao J, Wei H, Wu Z, Qian M, et al: Dual targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) prevents estrogen-dependent bone loss in mice. J Bone Miner Res. 34:765–776. 2019.PubMed/NCBI
32	van der Heide V, Möhnle P, Rink J, Briegel J and Kreth S: Down-regulation of MicroRNA-31 in CD4+ T cells contributes to immunosuppression in human sepsis by promoting TH2 skewing. Anesthesiology. 124:908–922. 2016. View Article : Google Scholar : PubMed/NCBI
33	Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
34	Pusztai L, Karn T, Safonov A, Abu-Khalaf MM and Bianchini G: New strategies in breast cancer: Immunotherapy. Clin Cancer Res. 22:2105–2110. 2016. View Article : Google Scholar : PubMed/NCBI
35	McArthur HL and Page DB: Immunotherapy for the treatment of breast cancer: Checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. Clin Adv Hematol Oncol. 14:922–933. 2016.PubMed/NCBI
36	Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L and Rimm DL: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 20:2773–2782. 2014. View Article : Google Scholar : PubMed/NCBI
37	Sinha P, Clements VK and Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 174:636–645. 2005. View Article : Google Scholar : PubMed/NCBI
38	Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721. 2005. View Article : Google Scholar : PubMed/NCBI
39	Friedl P and Alexander S: Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell. 147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
40	Mullauer FB, Kessler JH and Medema JP: Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs. 21:215–227. 2010. View Article : Google Scholar : PubMed/NCBI
41	Petrie RJ and Yamada KM: At the leading edge of three-dimensional cell migration. J Cell Sci. 125:5917–5926. 2012.PubMed/NCBI
42	Akhshi TK, Wernike D and Piekny A: Microtubules and actin crosstalk in cell migration and division. Cytoskeleton (Hoboken). 71:1–23. 2014. View Article : Google Scholar : PubMed/NCBI
43	Goode BL and Eck MJ: Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem. 76:593–627. 2007. View Article : Google Scholar : PubMed/NCBI
44	Kovar DR: Molecular details of formin-mediated actin assembly. Curr Opin Cell Biol. 18:11–17. 2006. View Article : Google Scholar : PubMed/NCBI
45	Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
46	Yu FX and Guan KL: The Hippo pathway: Regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
47	Zhang Y, Xiao Y, Dong Q, Ouyang W and Qin Q: Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro. J Food Sci. 84:904–910. 2019. View Article : Google Scholar : PubMed/NCBI
48	Pan D: The hippo signaling pathway in development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
49	Zhao B, Li L, Lei Q and Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
50	Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M and Hiraga T: Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev. 25:293–299. 1999. View Article : Google Scholar : PubMed/NCBI